Cpwm LLC Buys Shares of 3,514 Novartis AG (NVS)

Cpwm LLC bought a new position in Novartis AG (NYSE:NVS) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 3,514 shares of the company’s stock, valued at approximately $303,000.

A number of other hedge funds have also recently modified their holdings of NVS. Stelac Advisory Services LLC bought a new stake in shares of Novartis during the 3rd quarter worth about $113,000. Columbia Asset Management bought a new stake in shares of Novartis during the 3rd quarter worth about $126,000. Quad Cities Investment Group LLC bought a new stake in shares of Novartis during the 2nd quarter worth about $139,000. Howe & Rusling Inc. boosted its stake in shares of Novartis by 50.9% during the 3rd quarter. Howe & Rusling Inc. now owns 1,705 shares of the company’s stock worth $147,000 after acquiring an additional 575 shares in the last quarter. Finally, Monument Capital Management boosted its stake in shares of Novartis by 190.8% during the 3rd quarter. Monument Capital Management now owns 1,716 shares of the company’s stock worth $148,000 after acquiring an additional 1,126 shares in the last quarter. 11.20% of the stock is currently owned by institutional investors.

NVS has been the subject of several recent analyst reports. Goldman Sachs Group upgraded Novartis from a “neutral” rating to a “conviction-buy” rating in a research note on Friday, November 16th. Bank of America upgraded Novartis from an “underperform” rating to a “buy” rating and set a $74.71 price target for the company in a research note on Monday, September 10th. Zacks Investment Research downgraded Novartis from a “hold” rating to a “sell” rating in a research note on Wednesday, August 29th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novartis in a research note on Thursday, October 18th. Finally, Cowen upgraded Novartis from a “market perform” rating to an “outperform” rating and set a $88.03 target price for the company in a research note on Sunday, December 2nd. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $85.91.

Shares of NYSE:NVS opened at $87.08 on Friday. Novartis AG has a twelve month low of $72.30 and a twelve month high of $94.19. The company has a market cap of $209.68 billion, a P/E ratio of 18.10, a price-to-earnings-growth ratio of 2.01 and a beta of 0.74. The company has a quick ratio of 0.96, a current ratio of 1.20 and a debt-to-equity ratio of 0.29.

Novartis (NYSE:NVS) last announced its earnings results on Thursday, October 18th. The company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.01. Novartis had a return on equity of 15.81% and a net margin of 25.98%. The firm had revenue of $12.78 billion during the quarter, compared to the consensus estimate of $12.88 billion. During the same quarter in the prior year, the company earned $1.29 EPS. The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. On average, equities research analysts forecast that Novartis AG will post 5.17 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/12/08/cpwm-llc-buys-shares-of-3514-novartis-ag-nvs.html.

About Novartis

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Recommended Story: What Is An Exchange-Traded Fund (ETF)?

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply